Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up

被引：50

作者：

Giaccone, Giuseppe ^{[1
]}

Kim, Chul ^{[1
]}

机构：

[1] Cornell Univ, Weill Cornell Med, Washington, DC USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

Thymic carcinoma; Pembrolizumab; Survival; Response;

D O I：

10.1016/j.jtho.2020.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab induces durable responses in patients with thymic carcinoma. Careful selection of patients and monitoring of toxicities are warranted. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：483 / 485

页数：3

共 5 条

[1] Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial [J].

Cho, Jinhyun ;

Kim, Hae Su ;

Ku, Bo Mi ;

Choi, Yoon-La ;

Cristescu, Razvan ;

Han, Joungho ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Park, Keunchil ;

Ahn, Myung-Ju .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (24) :2162-+

[2] Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study [J].

Giaccone, Giuseppe ;

Kim, Chul ;

Thompson, Jillian ;

McGuire, Colleen ;

Kallakury, Bhaskar ;

Chahine, Joeffrey J. ;

Manning, Maria ;

Mogg, Robin ;

Blumenschein, Wendy M. ;

Tan, Ming T. ;

Subramaniam, Deepa S. ;

Liu, Stephen V. ;

Kaplan, Ian M. ;

McCutcheon, Justine N. .

LANCET ONCOLOGY, 2018, 19 (03) :347-355

[3] Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study [J].

Katsuya, Yuki ;

Horinouchi, Hidehito ;

Seto, Takashi ;

Umemura, Shigeki ;

Hosomi, Yukio ;

Satouchi, Miyako ;

Nishio, Makoto ;

Kozuki, Toshiyuki ;

Hida, Toyoaki ;

Sukigara, Tamie ;

Nakamura, Kenichi ;

Kuchiba, Aya ;

Ohe, Yuichiro .

EUROPEAN JOURNAL OF CANCER, 2019, 113 :78-86

[4] Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study [J].

Long, Georgina, V ;

Dummer, Reinhard ;

Humid, Omid ;

Gajewski, Thomas F. ;

Caglevic, Christian ;

Dalle, Stephan ;

Arance, Ana ;

Carlino, Matteo S. ;

Grob, Jean-Jacques ;

Kim, Tae Min ;

Demidov, Lev ;

Robert, Caroline ;

Larkin, James ;

Anderson, James R. ;

Maleski, Janet ;

Jones, Mark ;

Diede, Scott J. ;

Mitchell, Tara C. .

LANCET ONCOLOGY, 2019, 20 (08) :1083-1097

[5] Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma [J].

Rajan, Arun ;

Heery, Christopher R. ;

Thomas, Anish ;

Mammen, Andrew L. ;

Perry, Susan ;

Coyne, Geraldine O'Sullivan ;

Guha, Udayan ;

Berman, Arlene ;

Szabo, Eva ;

Madan, Ravi A. ;

Ballester, Leomar Y. ;

Pittaluga, Stefania ;

Donahue, Renee N. ;

Tsai, Yo-Ting ;

Lepone, Lauren M. ;

Chin, Kevin ;

Ginty, Fiona ;

Sood, Anup ;

Hewitt, Stephen M. ;

Schlom, Jeffrey ;

Hassan, Raffit ;

Gulley, James L. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

← 1 →